Global CNS Specific Antisense Oligonucleotides Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 87

Published Date: 02 Jan 2024

Category: Service & Software

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global CNS Specific Antisense Oligonucleotides market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.

The Global Info Research report includes an overview of the development of the CNS Specific Antisense Oligonucleotides industry chain, the market status of Hospital Pharmacies (Polyneuropathy Treatment, Spinal Muscular Atrophy (SMA) Treatment), Retail Pharmacies (Polyneuropathy Treatment, Spinal Muscular Atrophy (SMA) Treatment), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of CNS Specific Antisense Oligonucleotides.

Regionally, the report analyzes the CNS Specific Antisense Oligonucleotides markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global CNS Specific Antisense Oligonucleotides market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the CNS Specific Antisense Oligonucleotides market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the CNS Specific Antisense Oligonucleotides industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Polyneuropathy Treatment, Spinal Muscular Atrophy (SMA) Treatment).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the CNS Specific Antisense Oligonucleotides market.

Regional Analysis: The report involves examining the CNS Specific Antisense Oligonucleotides market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the CNS Specific Antisense Oligonucleotides market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to CNS Specific Antisense Oligonucleotides:
Company Analysis: Report covers individual CNS Specific Antisense Oligonucleotides players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards CNS Specific Antisense Oligonucleotides This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail Pharmacies).

Technology Analysis: Report covers specific technologies relevant to CNS Specific Antisense Oligonucleotides. It assesses the current state, advancements, and potential future developments in CNS Specific Antisense Oligonucleotides areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the CNS Specific Antisense Oligonucleotides market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
CNS Specific Antisense Oligonucleotides market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
Polyneuropathy Treatment
Spinal Muscular Atrophy (SMA) Treatment
Huntington’s Disease Treatment

Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by players, this report covers
Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe CNS Specific Antisense Oligonucleotides product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CNS Specific Antisense Oligonucleotides, with revenue, gross margin and global market share of CNS Specific Antisense Oligonucleotides from 2019 to 2024.
Chapter 3, the CNS Specific Antisense Oligonucleotides competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and CNS Specific Antisense Oligonucleotides market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of CNS Specific Antisense Oligonucleotides.
Chapter 13, to describe CNS Specific Antisense Oligonucleotides research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of CNS Specific Antisense Oligonucleotides
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of CNS Specific Antisense Oligonucleotides by Type
        1.3.1 Overview: Global CNS Specific Antisense Oligonucleotides Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type in 2023
        1.3.3 Polyneuropathy Treatment
        1.3.4 Spinal Muscular Atrophy (SMA) Treatment
        1.3.5 Huntington’s Disease Treatment
    1.4 Global CNS Specific Antisense Oligonucleotides Market by Application
        1.4.1 Overview: Global CNS Specific Antisense Oligonucleotides Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital Pharmacies
        1.4.3 Retail Pharmacies
        1.4.4 Online Pharmacies
    1.5 Global CNS Specific Antisense Oligonucleotides Market Size & Forecast
    1.6 Global CNS Specific Antisense Oligonucleotides Market Size and Forecast by Region
        1.6.1 Global CNS Specific Antisense Oligonucleotides Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global CNS Specific Antisense Oligonucleotides Market Size by Region, (2019-2030)
        1.6.3 North America CNS Specific Antisense Oligonucleotides Market Size and Prospect (2019-2030)
        1.6.4 Europe CNS Specific Antisense Oligonucleotides Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size and Prospect (2019-2030)
        1.6.6 South America CNS Specific Antisense Oligonucleotides Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa CNS Specific Antisense Oligonucleotides Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Akcea Therapeutics, Inc.
        2.1.1 Akcea Therapeutics, Inc. Details
        2.1.2 Akcea Therapeutics, Inc. Major Business
        2.1.3 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.1.4 Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Akcea Therapeutics, Inc. Recent Developments and Future Plans
    2.2 Ionis Pharmaceuticals Inc.
        2.2.1 Ionis Pharmaceuticals Inc. Details
        2.2.2 Ionis Pharmaceuticals Inc. Major Business
        2.2.3 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.2.4 Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Ionis Pharmaceuticals Inc. Recent Developments and Future Plans
    2.3 Biogen Inc.
        2.3.1 Biogen Inc. Details
        2.3.2 Biogen Inc. Major Business
        2.3.3 Biogen Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.3.4 Biogen Inc. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Biogen Inc. Recent Developments and Future Plans
    2.4 Sarepta Therapeutics
        2.4.1 Sarepta Therapeutics Details
        2.4.2 Sarepta Therapeutics Major Business
        2.4.3 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Product and Solutions
        2.4.4 Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Sarepta Therapeutics Recent Developments and Future Plans
    2.5 Wave Life Sciences Ltd.
        2.5.1 Wave Life Sciences Ltd. Details
        2.5.2 Wave Life Sciences Ltd. Major Business
        2.5.3 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.5.4 Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Wave Life Sciences Ltd. Recent Developments and Future Plans
    2.6 Dynacure
        2.6.1 Dynacure Details
        2.6.2 Dynacure Major Business
        2.6.3 Dynacure CNS Specific Antisense Oligonucleotides Product and Solutions
        2.6.4 Dynacure CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Dynacure Recent Developments and Future Plans
    2.7 ProQR Therapeutics N.V.
        2.7.1 ProQR Therapeutics N.V. Details
        2.7.2 ProQR Therapeutics N.V. Major Business
        2.7.3 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.7.4 ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 ProQR Therapeutics N.V. Recent Developments and Future Plans
    2.8 Stroke Therapeutic Inc.
        2.8.1 Stroke Therapeutic Inc. Details
        2.8.2 Stroke Therapeutic Inc. Major Business
        2.8.3 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
        2.8.4 Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Stroke Therapeutic Inc. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global CNS Specific Antisense Oligonucleotides Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of CNS Specific Antisense Oligonucleotides by Company Revenue
        3.2.2 Top 3 CNS Specific Antisense Oligonucleotides Players Market Share in 2023
        3.2.3 Top 6 CNS Specific Antisense Oligonucleotides Players Market Share in 2023
    3.3 CNS Specific Antisense Oligonucleotides Market: Overall Company Footprint Analysis
        3.3.1 CNS Specific Antisense Oligonucleotides Market: Region Footprint
        3.3.2 CNS Specific Antisense Oligonucleotides Market: Company Product Type Footprint
        3.3.3 CNS Specific Antisense Oligonucleotides Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global CNS Specific Antisense Oligonucleotides Consumption Value and Market Share by Type (2019-2024)
    4.2 Global CNS Specific Antisense Oligonucleotides Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2024)
    5.2 Global CNS Specific Antisense Oligonucleotides Market Forecast by Application (2025-2030)

6 North America
    6.1 North America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2030)
    6.2 North America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2030)
    6.3 North America CNS Specific Antisense Oligonucleotides Market Size by Country
        6.3.1 North America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2030)
        6.3.2 United States CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        6.3.3 Canada CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        6.3.4 Mexico CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2030)
    7.2 Europe CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2030)
    7.3 Europe CNS Specific Antisense Oligonucleotides Market Size by Country
        7.3.1 Europe CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2030)
        7.3.2 Germany CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        7.3.3 France CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        7.3.5 Russia CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        7.3.6 Italy CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific CNS Specific Antisense Oligonucleotides Market Size by Region
        8.3.1 Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Region (2019-2030)
        8.3.2 China CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        8.3.3 Japan CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        8.3.4 South Korea CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        8.3.5 India CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        8.3.7 Australia CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)

9 South America
    9.1 South America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2030)
    9.2 South America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2030)
    9.3 South America CNS Specific Antisense Oligonucleotides Market Size by Country
        9.3.1 South America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2030)
        9.3.2 Brazil CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        9.3.3 Argentina CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa CNS Specific Antisense Oligonucleotides Market Size by Country
        10.3.1 Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2030)
        10.3.2 Turkey CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)
        10.3.4 UAE CNS Specific Antisense Oligonucleotides Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 CNS Specific Antisense Oligonucleotides Market Drivers
    11.2 CNS Specific Antisense Oligonucleotides Market Restraints
    11.3 CNS Specific Antisense Oligonucleotides Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 CNS Specific Antisense Oligonucleotides Industry Chain
    12.2 CNS Specific Antisense Oligonucleotides Upstream Analysis
    12.3 CNS Specific Antisense Oligonucleotides Midstream Analysis
    12.4 CNS Specific Antisense Oligonucleotides Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global CNS Specific Antisense Oligonucleotides Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global CNS Specific Antisense Oligonucleotides Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global CNS Specific Antisense Oligonucleotides Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global CNS Specific Antisense Oligonucleotides Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Akcea Therapeutics, Inc. Company Information, Head Office, and Major Competitors
    Table 6. Akcea Therapeutics, Inc. Major Business
    Table 7. Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 8. Akcea Therapeutics, Inc. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Akcea Therapeutics, Inc. Recent Developments and Future Plans
    Table 10. Ionis Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
    Table 11. Ionis Pharmaceuticals Inc. Major Business
    Table 12. Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 13. Ionis Pharmaceuticals Inc. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Ionis Pharmaceuticals Inc. Recent Developments and Future Plans
    Table 15. Biogen Inc. Company Information, Head Office, and Major Competitors
    Table 16. Biogen Inc. Major Business
    Table 17. Biogen Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 18. Biogen Inc. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Biogen Inc. Recent Developments and Future Plans
    Table 20. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
    Table 21. Sarepta Therapeutics Major Business
    Table 22. Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 23. Sarepta Therapeutics CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Sarepta Therapeutics Recent Developments and Future Plans
    Table 25. Wave Life Sciences Ltd. Company Information, Head Office, and Major Competitors
    Table 26. Wave Life Sciences Ltd. Major Business
    Table 27. Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 28. Wave Life Sciences Ltd. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Wave Life Sciences Ltd. Recent Developments and Future Plans
    Table 30. Dynacure Company Information, Head Office, and Major Competitors
    Table 31. Dynacure Major Business
    Table 32. Dynacure CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 33. Dynacure CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. Dynacure Recent Developments and Future Plans
    Table 35. ProQR Therapeutics N.V. Company Information, Head Office, and Major Competitors
    Table 36. ProQR Therapeutics N.V. Major Business
    Table 37. ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 38. ProQR Therapeutics N.V. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. ProQR Therapeutics N.V. Recent Developments and Future Plans
    Table 40. Stroke Therapeutic Inc. Company Information, Head Office, and Major Competitors
    Table 41. Stroke Therapeutic Inc. Major Business
    Table 42. Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Product and Solutions
    Table 43. Stroke Therapeutic Inc. CNS Specific Antisense Oligonucleotides Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Stroke Therapeutic Inc. Recent Developments and Future Plans
    Table 45. Global CNS Specific Antisense Oligonucleotides Revenue (USD Million) by Players (2019-2024)
    Table 46. Global CNS Specific Antisense Oligonucleotides Revenue Share by Players (2019-2024)
    Table 47. Breakdown of CNS Specific Antisense Oligonucleotides by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 48. Market Position of Players in CNS Specific Antisense Oligonucleotides, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 49. Head Office of Key CNS Specific Antisense Oligonucleotides Players
    Table 50. CNS Specific Antisense Oligonucleotides Market: Company Product Type Footprint
    Table 51. CNS Specific Antisense Oligonucleotides Market: Company Product Application Footprint
    Table 52. CNS Specific Antisense Oligonucleotides New Market Entrants and Barriers to Market Entry
    Table 53. CNS Specific Antisense Oligonucleotides Mergers, Acquisition, Agreements, and Collaborations
    Table 54. Global CNS Specific Antisense Oligonucleotides Consumption Value (USD Million) by Type (2019-2024)
    Table 55. Global CNS Specific Antisense Oligonucleotides Consumption Value Share by Type (2019-2024)
    Table 56. Global CNS Specific Antisense Oligonucleotides Consumption Value Forecast by Type (2025-2030)
    Table 57. Global CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024)
    Table 58. Global CNS Specific Antisense Oligonucleotides Consumption Value Forecast by Application (2025-2030)
    Table 59. North America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2024) & (USD Million)
    Table 60. North America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2025-2030) & (USD Million)
    Table 61. North America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024) & (USD Million)
    Table 62. North America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2025-2030) & (USD Million)
    Table 63. North America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2024) & (USD Million)
    Table 64. North America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2025-2030) & (USD Million)
    Table 65. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2024) & (USD Million)
    Table 66. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Type (2025-2030) & (USD Million)
    Table 67. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024) & (USD Million)
    Table 68. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Application (2025-2030) & (USD Million)
    Table 69. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2024) & (USD Million)
    Table 70. Europe CNS Specific Antisense Oligonucleotides Consumption Value by Country (2025-2030) & (USD Million)
    Table 71. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2024) & (USD Million)
    Table 72. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Type (2025-2030) & (USD Million)
    Table 73. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024) & (USD Million)
    Table 74. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Application (2025-2030) & (USD Million)
    Table 75. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Region (2019-2024) & (USD Million)
    Table 76. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value by Region (2025-2030) & (USD Million)
    Table 77. South America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2024) & (USD Million)
    Table 78. South America CNS Specific Antisense Oligonucleotides Consumption Value by Type (2025-2030) & (USD Million)
    Table 79. South America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024) & (USD Million)
    Table 80. South America CNS Specific Antisense Oligonucleotides Consumption Value by Application (2025-2030) & (USD Million)
    Table 81. South America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2024) & (USD Million)
    Table 82. South America CNS Specific Antisense Oligonucleotides Consumption Value by Country (2025-2030) & (USD Million)
    Table 83. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Type (2019-2024) & (USD Million)
    Table 84. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Type (2025-2030) & (USD Million)
    Table 85. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Application (2019-2024) & (USD Million)
    Table 86. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Application (2025-2030) & (USD Million)
    Table 87. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Country (2019-2024) & (USD Million)
    Table 88. Middle East & Africa CNS Specific Antisense Oligonucleotides Consumption Value by Country (2025-2030) & (USD Million)
    Table 89. CNS Specific Antisense Oligonucleotides Raw Material
    Table 90. Key Suppliers of CNS Specific Antisense Oligonucleotides Raw Materials
List of Figures
    Figure 1. CNS Specific Antisense Oligonucleotides Picture
    Figure 2. Global CNS Specific Antisense Oligonucleotides Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type in 2023
    Figure 4. Polyneuropathy Treatment
    Figure 5. Spinal Muscular Atrophy (SMA) Treatment
    Figure 6. Huntington’s Disease Treatment
    Figure 7. Global CNS Specific Antisense Oligonucleotides Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 8. CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application in 2023
    Figure 9. Hospital Pharmacies Picture
    Figure 10. Retail Pharmacies Picture
    Figure 11. Online Pharmacies Picture
    Figure 12. Global CNS Specific Antisense Oligonucleotides Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global CNS Specific Antisense Oligonucleotides Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market CNS Specific Antisense Oligonucleotides Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Region in 2023
    Figure 17. North America CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global CNS Specific Antisense Oligonucleotides Revenue Share by Players in 2023
    Figure 23. CNS Specific Antisense Oligonucleotides Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players CNS Specific Antisense Oligonucleotides Market Share in 2023
    Figure 25. Global Top 6 Players CNS Specific Antisense Oligonucleotides Market Share in 2023
    Figure 26. Global CNS Specific Antisense Oligonucleotides Consumption Value Share by Type (2019-2024)
    Figure 27. Global CNS Specific Antisense Oligonucleotides Market Share Forecast by Type (2025-2030)
    Figure 28. Global CNS Specific Antisense Oligonucleotides Consumption Value Share by Application (2019-2024)
    Figure 29. Global CNS Specific Antisense Oligonucleotides Market Share Forecast by Application (2025-2030)
    Figure 30. North America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 40. France CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Region (2019-2030)
    Figure 47. China CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 50. India CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa CNS Specific Antisense Oligonucleotides Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE CNS Specific Antisense Oligonucleotides Consumption Value (2019-2030) & (USD Million)
    Figure 64. CNS Specific Antisense Oligonucleotides Market Drivers
    Figure 65. CNS Specific Antisense Oligonucleotides Market Restraints
    Figure 66. CNS Specific Antisense Oligonucleotides Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of CNS Specific Antisense Oligonucleotides in 2023
    Figure 69. Manufacturing Process Analysis of CNS Specific Antisense Oligonucleotides
    Figure 70. CNS Specific Antisense Oligonucleotides Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.

Related Reports

Global CNS Specific Antisense Oligonucleotides Supply, Demand and Key Producers, 2023-2029

Global CNS Specific Antisense Oligonucleotides Supply, Demand and Key Producers, 2023-2029

date 31 Jan 2023

date Service & Software

The global CNS Specific Antisense Oligonucleotides market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Product Tags

CNS Specific Antisense Oligonucleotides

soil fertility

Image High Dynamic

Building Energy Modeling

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>